RemeGen’s Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren’s Syndrome

Telitacicept has become the world's first pSS drug to declare Phase II results YANTAI, China, Jan. 25, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company,...

Full "IntellAsia: Resources" article